Jacqueto Zephyr, PhD
About Jacqueto Zephyr, PhD
Jacqueto Zephyr, PhD, is a scientist specializing in enzymology, currently working at Nimbus Therapeutics. He has extensive experience in protein expression, enzyme kinetics, and molecular modeling, with a strong background in structural biology and drug design.
Work at Nimbus
Jacqueto Zephyr, PhD, currently serves as a Scientist in Enzymology at Nimbus Therapeutics. He has been in this role since 2021, contributing to the company's focus on drug discovery and development. His work involves applying his expertise in enzyme kinetics and inhibition to support the creation of novel therapeutics. Zephyr's role emphasizes collaboration within a multidisciplinary team, reflecting Nimbus Therapeutics' commitment to innovative scientific research.
Education and Expertise
Jacqueto Zephyr holds a Doctor of Philosophy (PhD) in Biochemistry from the University of Massachusetts Medical School, where he studied from 2015 to 2021. He also earned a Bachelor of Science (BS) in Chemistry from Stony Brook University. Earlier, he completed an Associate of Science (AS) in Mathematics at Suffolk County Community College. His educational background supports his expertise in protein expression, purification, enzyme kinetics, and molecular modeling, which are critical in his current scientific endeavors.
Background
Zephyr's professional background includes various research positions. He worked as an Undergraduate Research Assistant at Stony Brook University from 2013 to 2014 and later as a Research Assistant at the University of Chicago from 2014 to 2015. He pursued his doctoral studies at the University of Massachusetts Medical School, where he also served as a Postdoctoral Research Associate for three months in 2021. This diverse experience has equipped him with a strong foundation in structural biology and enzymology.
Achievements
Throughout his career, Jacqueto Zephyr has developed skills in protein expression and purification, which support structural biology research. He has contributed to the advancement of enzyme kinetics and inhibition, playing a role in the development of new therapeutic approaches. His current focus includes expanding his expertise to encompass biologics and RNA-drugs, demonstrating a commitment to advancing his scientific knowledge and capabilities.